Fierce Biotech April 22, 2024
The twin clinical testing giants Labcorp and Quest Diagnostics have each, in the past week, added to their portfolios new blood tests that aim to peek into the workings of the human brain.
First, Labcorp announced the availability of a commercial test for glial fibrillary acidic protein, a biomarker released into the bloodstream by certain cells within the brain following neurological damage.
The company said the GFAP immunoassay could help track the early progression of diseases such as Alzheimer’s, multiple sclerosis or glioblastoma as well as help identify traumatic brain injuries.
Labcorp’s blood-based neurology catalog also includes biomarker tests for the Alzheimer’s hallmark proteins of beta amyloid and tau as well as for neurofilament light chain, which has been...
Today's Sponsors
Today's Sponsor